Company: BSX
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0000885725-25-000041
Chunk: 127

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 8
Chunk 127
---
 corroborated by, observable market data by correlation or other means. The following are the balances of our derivative and nonderivative assets and liabilities: Location on Unaudited Consolidated Balance Sheets(1)As of(in millions)June 30, 2025December 31, 2024Derivative and Nonderivative Assets:   Designated Hedging Instruments  Forward currency contractsOther current assets$63 $149 Forward currency contractsOther long-term assets2 79   65 228 Non-Designated Hedging Instruments   Forward currency contractsOther current assets26 156 Total Derivative and Nonderivative Assets $91 $384 Derivative and Nonderivative Liabilities:   Designated Hedging Instruments  Forward currency contractsOther current liabilities$134 $1 Forward currency contractsOther long-term liabilities161 0 Foreign currency-denominated debt(2)Long-term debt1,050 930   1,346 931 Non-Designated Hedging Instruments   Forward currency contractsOther current liabilities70 59 Total Derivative and Nonderivative Liabilities $1,416 $990 (1) We classify derivative and nonderivative assets and liabilities as current when the settlement date of the contract is one year or less.(2) Foreign currency-denominated debt is the €900 million debt principal associated with our December 2027 Notes designated as a net investment hedge. A portion of this notional is subject to de-designation and re-designation based on changes in the underlying hedged item.

18

Recurring Fair Value MeasurementsOn a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:•Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.•Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.•Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants